Vertex Pharmaceuticals VRTX Interest Expense
Discontinued — last reported Q4 '25
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's interest expense?
- Vertex Pharmaceuticals (VRTX) reported interest expense of $3.3M in Q4 2025.
- How has Vertex Pharmaceuticals's interest expense changed year-over-year?
- Vertex Pharmaceuticals's interest expense increased by 17.9% year-over-year, from $2.8M to $3.3M.
- What is the long-term trend for Vertex Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's interest expense has grown at a -31.8% compound annual growth rate (CAGR), from -$61.5M to $13.3M.
- What does interest expense mean?
- The cost of borrowing money, such as interest paid on loans or bonds.
- How do you interpret interest expense?
- A decrease indicates lower debt levels or improved credit terms, while an increase may signal higher leverage or rising interest rates.
- How does interest expense compare across companies?
- Standard metric for assessing financial risk and the cost of debt across all capital-intensive industries.